abstract |
The present invention describes a new method and new combination products for the therapy of neurological and other conditions which respond to dopaminergic therapies and especially to L-DOPA (L-Dihydroxy-Phenylalanine) based on the use of L-DOPA esters, especially of L-DOPA glycerol ester and L-DOPA Cholin Ester. |